2022 News Releases

ATCC announced a new line of products, CAR-T Target luciferase reporter cell lines, that will support immuno-oncology (IO) discovery and development of novel immunotherapies.

ATCC announced that is has received an award by the NCI to collect, process, and manage biological specimens for use in long-term epidemiology cancer research studies for the DCEG Field and Biospecimen Support Services program.

ATCC announces that it has made two key promotions within its leadership team.

ATCC announced that it has been awarded two contracts from Gennova Biopharmaceuticals Limited to continue its work with the biotechnology company on a diagnostic test and vaccine for Leishmaniasis.

ATCC Announces Two Projects from the U.S. Department of Agriculture’s Chief Scientific In-House Research Agency, the Agricultural Research Service

ATCC announced that it has entered into an agreement with QIAGEN to provide them with sequencing data from its collection of cell lines to be included in QIAGEN’s databases for biotechnology and pharmaceutical companies for research purposes.

ATCC received a task order contract, with a ceiling value of $5.6 million from NCI to receive, process, store, analyze, and distribute clinical specimens related to different cancer types.

ATCC received a task order contract, with a ceiling value of $1.9 million from NIAID to develop well-characterized challenge material (WCCM) for therapeutic development.

ATCC has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA) to identify and characterize novel therapeutic approaches to viruses of global health concern.

ATCC has been awarded a five-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the CDC to support the National Health and Nutrition Examination Survey (NHANES).

ATCC announced that it has been awarded a contract with Leidos Biomedical Research for the continued production, characterization, and distribution of next-generation cancer models (NGCM).